MedPath

Effects of continuous exercise on time spent in euglycemia and inflammation under the treatment of insulin degludec in patients with type 1 diabetes

Phase 1
Conditions
Diabetes mellitus Type 1
Therapeutic area: Body processes [G] - Immune system processes [G12]
Registration Number
EUCTR2017-000922-37-AT
Lead Sponsor
Medical University of Graz
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
10
Inclusion Criteria

1) Type 1 Diabetes
2) Aged: 18 – 65 years (both inclusive)
3) A1c 7 - 9% (53 – 75 mmol.mol-1) (both inclusive)
4) Fasting c-peptide < 0.25 nmol.l-1 [21]
5) Intensified insulin therapy
6) Diabetes diagnosed > 12 months
7) BMI 18.5 – 27 kg/m2 (both inclusive)
8) more 150 min per week exercising with moderate intensity or more than 75 min per week exercising with high intensity
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1) Diabetic long-term complications
2) Female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods
3) Illness or disease, that confound the study results
4) Interference with insulin action
5) Suspected allergy to trial products
6) Addiction to alcohol
7) Use of drugs
8) Mental incapacity

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath